when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

NOVARTIS · news · pharmadog

← back to NOVARTIS

News mentioning NOVARTIS

367 stories

Jun 12, 26STAT+: At hospital finance conference, a call to end the friction that’s keeping costs highstat

Jun 11, 26STAT+: An obesity drug deep-dive, and peptides move mainstreamstat

Jun 11, 26Nonprofit buys experimental cancer drug to maintain patient accessstat

Jun 11, 26Study highlights influence of socioeconomic status on children’s brain developmentstat

Jun 11, 26STAT+: Abridge inks deals with Nvidia and Lillystat

Jun 11, 26STAT+: A suspicious denial pattern in Medicare Advantagestat

Jun 11, 26Sensorion axes hearing loss program; Novartis' biomarker data in muscular dystrophyendpoints

Jun 11, 26Novartis RNA drug acquired in $12B Avidity deal notches a trial winbiopharma dive

Jun 11, 26STAT+: Novartis doubles down on molecular glue strategystat

Jun 11, 26J&J looks to widen Imaavy’s use; $300M backs rare disease drug launchbiopharma dive

Jun 11, 26STAT+: Enliven Therapeutics’ leukemia drug shows promise in new studystat

Jun 10, 26Novartis and Orionis strike second molecular glue deal for $40M upfrontendpoints

Jun 8, 26Incyte to buy blood disorder drug in possibly $2B dealbiopharma dive

Jun 3, 26Legend surges on early data for ‘in vivo’ lymphoma cell therapybiopharma dive

Jun 2, 26Celcuity breast cancer drug misses ‘lofty’ expectations in ASCO-spotlighted trialbiopharma dive

Jun 2, 26Fulcrum exploring a potential sale after FDA sidelined its sickle cell drugbiopharma dive

Jun 2, 26Male contraception startup closes $92.5M Series B; Novartis bets on actiniumendpoints

May 19, 26STAT+: Pharmalittle: We’re reading about a Supreme Court setback for pharma, TrumpRx expands and much morestat

May 19, 26Relay drug shows early promise against rare blood vessel diseasesbiopharma dive

May 18, 26STAT+: Supreme Court rejects challenge to Medicare drug price negotiationstat

May 13, 26Assertio accepts new buyout bid; AI biotech Isomorphic banks $2Bbiopharma dive

May 8, 26Post–T-DXd Sacituzumab Govitecan Plus Trastuzumab Yields Low ORR in HER2+ Metastatic Breast Canceronclive

May 8, 26Capivasertib/Fulvestrant Yields Numerical OS Advantage in PIK3CA/AKT1/PTEN–Altered Breast Canceronclive

May 7, 26Entrada shares dive as Duchenne results disappointbiopharma dive

May 7, 26Amgen adds $300M to Puerto Rico budget; Novartis to exit oral drug factory in Germanyendpoints

May 4, 26Celcuity strengthens case for ASCO-spotlighted breast cancer drugbiopharma dive

Apr 30, 26Merck still sees ‘compelling’ outlook for Terns leukemia drugbiopharma dive

Apr 30, 26STAT+: Five-way obesity drug is super effective — in micestat

Apr 30, 26Novartis unveils North Carolina factory as final new build in $23B US expansionendpoints

Apr 28, 26STAT+: Boehringer’s obesity drug shows 16.6% weight loss; more data neededstat

← prevpage 12 of 13next →